Bristol-Myers Squibb Advances BMS-986278 Through Key Heart Safety Study

Bristol-Myers Squibb Company (BMY) announced an update on their ongoing clinical study.

Bristol-Myers Squibb Co. (BMY) is running a Phase 1 study called “A Study to Evaluate the Effect of BMS-986278 on Cardiac Repolarization in Healthy Participants.” The aim is to see if this new drug affects heart rhythm, a key safety step that can shape the future value of the broader pipeline.

The trial tests the oral drug BMS-986278 versus placebo and a known antibiotic called moxifloxacin. The goal is to measure any change in heart electrical activity and confirm a clean safety margin before moving into larger patient studies.

The study uses a randomized crossover design, so each healthy volunteer cycles through several treatment periods. It is double-blind with placebo and positive control arms, meaning neither participants nor staff know who gets which treatment, and the main focus is treatment-related heart safety.

The trial was first submitted on Feb. 12, 2026, and is currently listed as recruiting. The latest update was posted on Mar. 16, 2026, signaling active operational progress, though primary and final completion dates have not yet been disclosed.

For investors, this update signals that BMY is advancing BMS-986278 through a key regulatory safety hurdle that many cardio-risk sensitive drugs must clear. A favorable QT result can de-risk the asset, support later-stage plans, and modestly lift sentiment versus peers with earlier or less validated pipelines.

Competitors in cardio-metabolic and inflammation drug spaces are also pushing assets through similar heart safety work, so timing and clarity matter. Any clean readout could strengthen BMY’s negotiating position in partnerships and help underpin long-term growth expectations rather than drive near-term stock spikes.

The study is ongoing and has been recently updated, with further details available on the ClinicalTrials.gov portal under identifier NCT07422298.

To learn more about BMY’s potential, visit the Bristol-Myers Squibb Company drug pipeline page.